Ipamorelin: adverse events and evidence limits
An intravenous ipamorelin trial after bowel resection lasting up to seven days reported treatment-emergent events. [1]
Its abstract does not establish event-specific frequencies or longer-term risks. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Treatment-emergent adverse events | Patients after bowel resection, intravenous ipamorelin for up to seven days | Reported in the trial; the abstract does not establish event-specific frequencies or longer-term risks | [1] |
References
- David E Beck et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. 10.1007/s00384-014-2030-8.